Pages
-
-
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers
-
-
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
-
-
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
-
-
Psilocybin microdosing does not affect emotion-related symptoms and processing
-
-
Psilocybin microdosing does not affect emotion-related symptoms and processing:
-
-
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial
-
-
A single administration of microbial D-alanine to healthy volunteers augments reaction to negative emotions: a comparison with D-serine
-
-
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
-
-
The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the sleep-promoting effects of tryptophan: A randomized placebo-controlled crossover study
-
-
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
-
-
Effects of chronic caffeine consumption on sleep and the sleep electroencephalogram in mice
-
-
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
-
-
Pharmacological interactions between brivaracetam and ethanol in healthy males
-
-
Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation
-
-
Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects
-
-
Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing
-
-
Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects
-
-
NS11821, a partial subtype-selective GABA(A) agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects
-
-
Optimizing the glutamatergic challenge model for psychosis, using S(+)-ketamine to induce psychomimetic symptoms in healthy volunteers
-
-
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
-
-
Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness
-
-
Does olanzapine inhibit the psychomimetic effects of Delta(9)-tetrahydrocannabinol?
-
-
Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals
-
-
The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol
Pages